|
Apr 14
|
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
|
|
Apr 14
|
Roche’s Columvi combo gains EC approval for DLBCL
|
|
Apr 14
|
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
|
|
Apr 10
|
Tempest hits funding block for Phase III liver cancer drug-in-waiting
|
|
Apr 10
|
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial
|
|
Apr 9
|
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
|
|
Apr 9
|
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
|
|
Apr 9
|
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca
|
|
Apr 7
|
Sarepta and Roche aim to resume paused Elevidys trials following patient death
|
|
Mar 17
|
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
|
|
Mar 14
|
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
|
|
Mar 14
|
Roche Diagnostics supports UK eye cancer AI initiative
|
|
Mar 14
|
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
|
|
Mar 13
|
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
|
|
Mar 13
|
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
|
|
Mar 13
|
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
|
|
Mar 12
|
Roche, Zealand sign deal: What it means for weight loss drug space
|
|
Mar 12
|
Novo Nordisk Is Falling. Competition Is a Killer.
|
|
Mar 12
|
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
|
|
Mar 12
|
Novo Nordisk, Starbucks shares slumping: Trending Tickers
|